Available as Global test only. Markers are CD7, CD11b, CD13, CD14, CD15, CD16, CD19, CD2, CD33, CD34, CD38, CD4, CD45, CD56, CD64, CD65, CD87, CD117, CD371, HLA-DR (20 markers). This panel can detect MRD at the 0.01% level.
MRD assessment has the potential to improve outcomes for patients with acute myeloid leukemia (AML). It can be used as a prognostic/predictive assay for risk assessment and treatment decision-making and to monitor for relapse.
- Bone marrow aspirate: 2-3 mL, first pull. EDTA preferred. Sodium heparin tube acceptable. Lithium heparin or ACD (pale yellow/no gel separator) not acceptable. Please provide recent CBC report.
Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
24 hours